Pharma
Natco Pharma Launches India’s First Generic Semaglutide Multi-Dose Vials
Affordable GLP-1 therapy introduced with multi-dose vial format to improve diabetes treatment access
Natco Pharma Limited has announced the launch of India’s first generic semaglutide injection in a multi-dose vial format, marking a significant development in the country’s diabetes treatment landscape. The company disclosed the launch through a regulatory filing under Regulation 30 of SEBI listing requirements, positioning itself as a pioneer in this delivery format for diabetes and weight management therapy.
Product Launch and Regulatory Approval
Natco Pharma received approval from the Central Drugs Standard Control Organisation (CDSCO) in February 2026 to manufacture and market generic semaglutide in India. The approval covers both multi-dose vial and pen device formats, based on clinical comparison studies. The launch aligns with the first day of patent expiry, reflecting a strategically timed market entry.
Key product details include:
Product Launch and Regulatory Approval
Natco Pharma received approval from the Central Drugs Standard Control Organisation (CDSCO) in February 2026 to manufacture and market generic semaglutide in India. The approval covers both multi-dose vial and pen device formats, based on clinical comparison studies. The launch aligns with the first day of patent expiry, reflecting a strategically timed market entry.
Key product details include:
• Brand names: SEMANAT™ and SEMAFULL™
• Indication: Treatment of Type 2 diabetes mellitus
• Market position: First company in India to introduce semaglutide in multi-dose vial format
• Indication: Treatment of Type 2 diabetes mellitus
• Market position: First company in India to introduce semaglutide in multi-dose vial format
Comprehensive Product Portfolio
The company has introduced semaglutide across multiple strengths and pricing formats:
• 2 mg/1.5 mL:
Multi-dose vial: INR 1,290
Pen device: INR 4,000
Launch timeline: March 2026
• 4 mg/3 mL: Multi-dose vial: INR 1,290 Pen device: INR 4,200 Launch timeline: March 2026
• 8 mg/3 mL: Multi-dose vial: INR 1,750 Pen device: INR 4,500 Launch timeline: April 2026
• 4 mg/3 mL: Multi-dose vial: INR 1,290 Pen device: INR 4,200 Launch timeline: March 2026
• 8 mg/3 mL: Multi-dose vial: INR 1,750 Pen device: INR 4,500 Launch timeline: April 2026
Market Differentiation and Cost Advantages
Natco Pharma’s introduction of semaglutide in a vial format with customised syringes represents a notable advancement in drug delivery within this category. The multi-dose vial format offers an alternative to traditional pen devices, potentially improving ease of access and affordability for patients.
The pricing strategy highlights significant cost benefits, with the vial format estimated to be around 70% cheaper than pen devices and up to 90% more affordable than the innovator product. This positions it as one of the most cost-effective GLP-1 therapies available in India, enhancing accessibility for a larger patient population.
Strategic Business Approach
In addition to direct distribution, Natco Pharma plans to expand market reach through co-marketing partnerships with third parties. The pen device format is expected to be introduced in April 2026, providing patients and healthcare providers with multiple treatment delivery options.
The launch strengthens Natco Pharma’s presence in the generics segment while addressing the growing need for affordable diabetes management solutions, reinforcing its role in advancing accessible healthcare in India.
Natco Pharma’s introduction of semaglutide in a vial format with customised syringes represents a notable advancement in drug delivery within this category. The multi-dose vial format offers an alternative to traditional pen devices, potentially improving ease of access and affordability for patients.
The pricing strategy highlights significant cost benefits, with the vial format estimated to be around 70% cheaper than pen devices and up to 90% more affordable than the innovator product. This positions it as one of the most cost-effective GLP-1 therapies available in India, enhancing accessibility for a larger patient population.
Strategic Business Approach
In addition to direct distribution, Natco Pharma plans to expand market reach through co-marketing partnerships with third parties. The pen device format is expected to be introduced in April 2026, providing patients and healthcare providers with multiple treatment delivery options.
The launch strengthens Natco Pharma’s presence in the generics segment while addressing the growing need for affordable diabetes management solutions, reinforcing its role in advancing accessible healthcare in India.
Affordable HealthcareDiabetes TreatmentGeneric Drugs India
